

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Diagnostics Assessment Programme

**Sepsis: The LightCycler SeptiFast Test MGRADE, SepsiTTest and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi**

### Provisional stakeholder list

<b>Manufacturer(s)</b> Abbott Laboratories Roche Diagnostics Molzym
<b>Manufacturer(s) of related technologies (not included in scope)</b> Alacrita LLP Anagnostics Hain Lifescience UK Ltd
<b>Professional groups</b> The Intensive Care Society Royal College of Anaesthetists Royal College of Pathologists Royal College of Physicians
<b>Patient/carers groups</b> Group B Strep Support UK Sepsis Trust
<b>Research groups</b> None
<b>Associated guideline groups</b> National Clinical Guidelines Centre
<b>External Assessment Group</b> School of Health and Related Research (SCHARR), University of Sheffield
<b>Others</b> Department of Health Healthcare Improvement Scotland NHS England Welsh Government

**Definitions:**Stakeholders

Individuals or organisations interested in a topic being evaluated by the Diagnostics Assessment Programme, and who register to become a stakeholder. For example, manufacturers of the technology, national organisations that represent healthcare professions who operate or use the results of the technology, national patient or carer organisations, NHS service providers and commissioners, statutory organisations and research organisations.

External Assessment Group (EAG)

An independent academic group commissioned by the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) that prepares a systematic review of the clinical and cost effectiveness of the technology(ies).